The Efficacy and Safety of Diluted Oral Phosphate Enema Versus Intravenous Sodium Glycerophosphate in The Treatment of Hypophosphatemia in ICU Patients
NCT ID: NCT06651892
Last Updated: 2025-06-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
42 participants
INTERVENTIONAL
2024-05-01
2024-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main question it aims to answer is:
can the investigators rely on phosphate enemas as an effective and safe treatment option for hypophosphatemia in critically ill adults, in the era of global shortage of parenteral nutrition solutions and the absence of defined guidelines for treatment of acute hypophosphatemia in those population.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Electrolytes Disturbances in Critically Ill Egyptian Patients
NCT06097104
0.9% NaCl/Dextrose 5% vs 0.45% NaCl/Dextrose 5% as Maintenance Intravenous Fluids in Critically Ill Children
NCT01301274
HYPOPhosphatemia in the Intensive Care: A One-day Point Prevalence Survey
NCT04201899
Protocolised Management of Phosphate Replacement Trial
NCT07288944
Efficacy of KCl Plus 0.9%NaCl Compare With KCl Plus 0.45%NaCl
NCT02721095
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Dose Calculation: as per hospital protocol and scientific reference(Crook, 2009) 0.32 mmol per kg for mild hypophosphatemia 0.64 mmol per kg for moderate hypophosphatemia
All participants will be reassessed the next day after the intervention and followed up for the occurrence of any side effects, then participants will be followed up again the day after. (Assessment of serum phosphate and sodium along with occurrence of diarrhea or any other side effects).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A - oral diluted phosphate enema
oral diluted phosphate enema
Enema Phosphates Sodium
oral diluted phosphate enema containing as a repletion strategy to replace phosphate in critically ill patients with acute hypophosphatemia.
Group B - intravenous sodium glycerophosphate
intravenous sodium glycerophosphate
Glycophos Injectable Product
intravenous sodium glycerophosphate as the standard of care or active control
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Enema Phosphates Sodium
oral diluted phosphate enema containing as a repletion strategy to replace phosphate in critically ill patients with acute hypophosphatemia.
Glycophos Injectable Product
intravenous sodium glycerophosphate as the standard of care or active control
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Serum phosphorus level less than 2.5mg/dl - between 1.5 - 2.5mg/dl
* Patients 18 years or older
Exclusion Criteria
* Serum Phosphorus level less than 1.5 mg/dL
* Patients on Non-peroral status
* Ileus (as paralytic ileus, post-operative)
* Any problem in gut integrity as (intestinal obstruction, Severe Malabsorption, severe diarrhea)
* Any form of ischemic gut (as mesenteric ischemia, mesenteric gastric occlusion, arterial venous insufficiency)
* Hemodynamically unstable patients
* Severe Hypocalcemia or Hypercalcemia at the beginning of the study (when iv phosphate is deemed inappropriate at the discretion of attending physician)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Al haram Hospital
Giza, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REC #270
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.